Source comparison
TB-4 vs TB-500: Which Peptide Works Better?
Fewer than 15% of researchers using TB-500 in their protocols realise they're not working with the full thymosin beta-4 molecule. They're using a synthetic 17–23 amino acid fragment designed to replicate the active region while solving stability problems that
This comparison does not assign a generated winner or score.
- Fewer than 15% of researchers using TB-500 in their protocols realise they're not working with the full thymosin beta-4 molecule. They're using a synthetic 17–23 amino acid fragment designed to replicate the active region while solving stability problems that make native TB-4 impractical for most lab applications. This isn't a substitution issue or a quality concern. It's a deliberate structural choice. TB-500 was engineered specifically because full-length TB-4 degrades rapidly, requires cold chain logistics most facilities can't support long-term, and costs significantly more per milligram for marginal functional gain in the majority of research contexts.
- Our team has guided hundreds of research facilities through peptide selection for regenerative and cellular signalling studies. The TB-4 vs TB-500 decision comes down to three factors most procurement teams overlook: molecular weight and receptor binding kinetics, in-solution stability under standard lab conditions, and whether your research question genuinely requires the full 43-amino-acid sequence or whether the active fragment delivers equivalent data.
- What is the difference between TB-4 and TB-500?
- TB-4 (thymosin beta-4) is the naturally occurring 43-amino-acid peptide found in mammalian tissue, while TB-500 is a synthetic 17–23 amino acid fragment derived from the active region (amino acids 17–23) of TB-4. TB-500 demonstrates comparable actin-binding activity and cellular migration effects to full-length TB-4 in most in vitro assays, with significantly improved shelf stability and lower cost per functional unit. The two are not identical. But for the majority of wound healing, angiogenesis, and tissue repair research applications, TB-500 replicates the key mechanisms without requiring the logistical burden of handling the full peptide.
- The misconception that TB-500 is 'fake TB-4' stems from vendor marketing and incomplete understanding of peptide fragment research. TB-500 was not designed as a cheaper substitute. It was engineered because the active site of TB-4 (the region responsible for actin sequestration and cellular motility) is localized to a specific sequence, and isolating that sequence eliminates degradation pathways present in the full molecule. This article covers the molecular structure differences that matter for stability, the functional overlap and divergence between the two peptides in regenerative research, and the practical decision framework for selecting one over the other based on your specific protocol requirements.